Tumour-agnostic drugs in paediatric cancers

The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case...

Descripción completa

Detalles Bibliográficos
Autores principales: Chisholm, Julia C., Carceller, Fernando, Marshall, Lynley V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217925/
https://www.ncbi.nlm.nih.gov/pubmed/32161367
http://dx.doi.org/10.1038/s41416-020-0770-5
_version_ 1783532689225154560
author Chisholm, Julia C.
Carceller, Fernando
Marshall, Lynley V.
author_facet Chisholm, Julia C.
Carceller, Fernando
Marshall, Lynley V.
author_sort Chisholm, Julia C.
collection PubMed
description The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.
format Online
Article
Text
id pubmed-7217925
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72179252021-03-12 Tumour-agnostic drugs in paediatric cancers Chisholm, Julia C. Carceller, Fernando Marshall, Lynley V. Br J Cancer Comment The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children. Nature Publishing Group UK 2020-03-12 2020-05-12 /pmc/articles/PMC7217925/ /pubmed/32161367 http://dx.doi.org/10.1038/s41416-020-0770-5 Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Comment
Chisholm, Julia C.
Carceller, Fernando
Marshall, Lynley V.
Tumour-agnostic drugs in paediatric cancers
title Tumour-agnostic drugs in paediatric cancers
title_full Tumour-agnostic drugs in paediatric cancers
title_fullStr Tumour-agnostic drugs in paediatric cancers
title_full_unstemmed Tumour-agnostic drugs in paediatric cancers
title_short Tumour-agnostic drugs in paediatric cancers
title_sort tumour-agnostic drugs in paediatric cancers
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217925/
https://www.ncbi.nlm.nih.gov/pubmed/32161367
http://dx.doi.org/10.1038/s41416-020-0770-5
work_keys_str_mv AT chisholmjuliac tumouragnosticdrugsinpaediatriccancers
AT carcellerfernando tumouragnosticdrugsinpaediatriccancers
AT marshalllynleyv tumouragnosticdrugsinpaediatriccancers

Ejemplares similares